Measles vaccine potency and Sero- conversion rates among infants receiving measles immunization in Ilorin, Kwara state, Nigeria.
| dc.contributor.author | Fowotade, A. | |
| dc.contributor.author | Okonko, I. O. | |
| dc.contributor.author | Nwabuisi, C. | |
| dc.contributor.author | Bakare, R. A. | |
| dc.contributor.author | Fadeyi, A. | |
| dc.contributor.author | Adu, F. D. | |
| dc.date.accessioned | 2026-02-27T13:42:09Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | This study was designed to assess the seroconversion rate of measles vaccine among infants receiving measles immunization in Ilorin, Nigeria. The pre- and post-measles vaccination sera of the children were tested using the Haemagglutination Inhibition test. The measles vaccines administered at the immunization centre were also tested for their potency using in-vitro titration method. Only 286 (71.5%) of the vacinees returned to give post-vaccination samples. All the infants screened had low pre-vaccination measles antibody titers. Thirty one (8.0%) of the infants had measles prior to vaccination. The seroconversion pattern showed that 196 (68.6%) of the infants developed protective antibody titers. Low seroconversion rate reported in this study was due to low vaccine potency. The titers of vaccines with low potency ranged between log10−1.0–log10−2.25 TCID/per dose. This was beside other non specific antiviral substances exhibited virus neutralizing activity. Only 3 (50%) of the 6 vaccine vials tested had virus titers of log10−3.25 to log10−3.5, which fell above the cut-off point recommended by the World Health Organization for measles vaccines. The sero-conversion rate of 68.6% observed among vaccinees is far lower than the immunity level of 95% required stopping measles transmission in an endemic community. Failure of 31.4% of these infants to sero-convert post vaccination can be attributed partly to administration of sub-potent vaccines. There is need for improvement and maintenance of effective vaccine cold chain system in Nigeria. There is need also for periodic monitoring of post-vaccination antibody titers as well as vaccine potency status in order to ensure development of protective seroconversion rates. | |
| dc.identifier.issn | 1532-1819 | |
| dc.identifier.issn | 1532-4230 | |
| dc.identifier.other | ui_art_fowotade_measles_2015 | |
| dc.identifier.other | Journal of Immunoassay and Immunochemistry, 36(2), pp. 195–209 | |
| dc.identifier.uri | https://repository.ui.edu.ng/handle/123456789/12703 | |
| dc.language.iso | en | |
| dc.publisher | Taylor & Francis | |
| dc.subject | measles vaccine | |
| dc.subject | sero-conversion | |
| dc.subject | developing countries | |
| dc.subject | potency | |
| dc.subject | infants | |
| dc.subject | immunization | |
| dc.subject | Nigeria | |
| dc.title | Measles vaccine potency and Sero- conversion rates among infants receiving measles immunization in Ilorin, Kwara state, Nigeria. | |
| dc.type | Article |
